World Investment Advisors LLC Buys New Shares in OPKO Health, Inc. (NASDAQ:OPK)

World Investment Advisors LLC purchased a new position in shares of OPKO Health, Inc. (NASDAQ:OPK) in the 3rd quarter, Holdings Channel reports. The firm purchased 40,717 shares of the biotechnology company’s stock, valued at approximately $61,000.

A number of other large investors also recently bought and sold shares of OPK. CIBC Asset Management Inc grew its stake in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 8,978 shares during the period. PFG Investments LLC boosted its holdings in OPKO Health by 2.5% in the second quarter. PFG Investments LLC now owns 960,965 shares of the biotechnology company’s stock valued at $1,201,000 after acquiring an additional 23,700 shares during the last quarter. American Century Companies Inc. purchased a new stake in OPKO Health during the second quarter valued at about $112,000. Y.D. More Investments Ltd acquired a new stake in OPKO Health during the second quarter worth about $1,840,000. Finally, Hollencrest Capital Management raised its holdings in shares of OPKO Health by 14.0% in the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 11,020 shares during the period. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 100,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were acquired at an average cost of $1.62 per share, with a total value of $162,000.00. Following the completion of the transaction, the chief executive officer now owns 211,612,405 shares in the company, valued at $342,812,096.10. The trade was a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought 1,304,255 shares of company stock valued at $2,024,605 over the last 90 days. 47.26% of the stock is owned by corporate insiders.

OPKO Health Stock Performance

Shares of NASDAQ:OPK opened at $1.57 on Friday. The business’s 50-day simple moving average is $1.54 and its 200 day simple moving average is $1.48. The company has a market cap of $1.07 billion, a P/E ratio of -8.26 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. OPKO Health, Inc. has a one year low of $0.85 and a one year high of $1.76.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OPK. Barrington Research reiterated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Thursday, September 26th. StockNews.com raised shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.